Fundamental Intelligent Building Blocks of the Intensive Care Unit (ICU) of the Future: Intelligent ICU of the Future
NCT ID: NCT03905668
Last Updated: 2025-06-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
71 participants
OBSERVATIONAL
2016-02-03
2028-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pervasive Sensing and AI in Intelligent ICU
NCT05127265
Neurosteer Bedside Monitoring System
NCT06718764
Utilizing Technology for Optimization of Pain Management and Mobilization in High Risk Cardiac Surgical ICU Patients
NCT04146727
Exploring the Use of AI-Assisted Video Monitoring to Predict Accidental Events in ICU Patients
NCT07307521
ICU-Recover Box 2.0, Smart Technology for Home Monitoring of ICU Patients
NCT07162948
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Delirium is another common complication of hospitalization that poses significant health problems in hospitalized patients. It is most prevalent in surgical ICU patients with diagnosis rates up to 80%. It is characterized by changes in cognition, activity level, consciousness, and alertness. Delirium typically leads to changes in activity level and alertness that pose additional health risks including risk of fall, inadequate mobilization, disturbed sleep, inadequate pain control, and negative emotions. All of these effects are difficult to monitor in real-time and further contribute to worsening of patient's cognitive abilities, inhibit recovery, and slow down the rehabilitation process. Though about a third of delirium cases can benefit from intervention, detecting and predicting delirium is still very limited in practice. Current Delirium assessments need to be performed by trained healthcare staff, are time consuming, and resource intensive. Due to the resources necessary to complete the assessment, delirium is often assessed twice per day, despite the transient nature of the disease state which can come and go undetected between the assessments. Jointly these obstacles demonstrate a dire need for real-time autonomous delirium detection.
The investigators hypothesize that the proposed model would be able to leverage accelerometer, electromyographic, and video data for the purpose of autonomously quantifying patient facial expressions such as pain, characterizing functional activities, and delirium status. Rationalizing that autonomous visual cue quantification and delirium detection can reduce nurse workload and can enable real-time pain and delirium monitoring. Early detection of delirium offers patients the best chance for good delirium treatment outcomes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ICU Patients
Adults in admitted to an ICU at University of Florida Health Gainesville with an expected length of stay greater than 24 hours which are not on any form of contact precaution or isolation. Patients will have continuous video, accelerometer, and electromyographic monitoring for up to seven days while in the ICU.
Video Monitoring
Patients may have video monitoring for up to seven days while in the ICU. The video system will be placed in an unobtrusive area in the patient's ICU room.
Accelerometer Monitoring
Patients may have accelerometer monitoring for up to seven days while in the ICU. Commercially available accelerometer units, which have been validated in previous clinical studies, will be used.
Electromyographic Monitoring
Patients may have electromyographic monitoring for up to seven days while in the ICU.
Noise Level Monitoring
Patients may have noise level monitoring (in decibels) for up to seven days while in the ICU.
Light Level Monitoring
Patients may have light level monitoring for up to seven days while in the ICU.
ICU Patient Friends/Family Members
Adult visitors of participating ICU patients that are willing to provide feedback to the learning algorithms.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Video Monitoring
Patients may have video monitoring for up to seven days while in the ICU. The video system will be placed in an unobtrusive area in the patient's ICU room.
Accelerometer Monitoring
Patients may have accelerometer monitoring for up to seven days while in the ICU. Commercially available accelerometer units, which have been validated in previous clinical studies, will be used.
Electromyographic Monitoring
Patients may have electromyographic monitoring for up to seven days while in the ICU.
Noise Level Monitoring
Patients may have noise level monitoring (in decibels) for up to seven days while in the ICU.
Light Level Monitoring
Patients may have light level monitoring for up to seven days while in the ICU.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individual has their name designated on a patient's informed consent form giving them permission to view and modify facial and activity data collected about that patient
Exclusion Criteria
* Patient is on any form of contact precaution or isolation
* Patient is unable to wear a Shimmer3 unit
ICU Patient Friends/Family:
* Age \< 18
* They are unable to answer short questions on a touch screen display
* They are unable to wear a proximity sensor
* They were not on the listed of designated individuals specified in their friend/family members informed consent form
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute for Biomedical Imaging and Bioengineering (NIBIB)
NIH
U.S. National Science Foundation
FED
National Institutes of Health (NIH)
NIH
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
University of Florida
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Azra Bihorac, MD
Role: PRINCIPAL_INVESTIGATOR
University of Florida
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UF Health Shands Hospital
Gainesville, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1750192
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
OCR20330
Identifier Type: OTHER
Identifier Source: secondary_id
IRB201900354 -N
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.